Biotech | May 21, 2022
AbbVie submits NDA for treatment of advanced Parkinson’s disease
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
The new lab is a testament to the Pondicherry Institute of Medical Sciences (PIMS)’s long-held values and traditions of striving for excellence and embracing newer innovations in order to deliver the best standard of training for their students
The patient, who was previously diagnosed with osteoarthritis, was prescribed hip replacement surgery as the best and most effective solution for his condition
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Risk management plans can serve as a safeguard, helping manufacturers prepare for and respond to hazards that could lead to drug supply disruptions and shortages
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
Pharmapack Europe recognizes excellence and innovation from exhibitors across connected devices, sustainability, supply chain logistics, route of administration, and packaging innovation, as well from the wider industry for patient-centric design and eco-design
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
Subscribe To Our Newsletter & Stay Updated
